A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Parallel evolution of cardiotonic steroid resistance in vertebrates == Several studies have detailed the evolution of cardiotonic steroid resistance of the alpha-subunit gene family of Na/K-ATPase (ATP1A) in vertebrates via amino acid substitutions most often located in the first extracellular loop domain. Amino acid substitutions conferring cardiotonic steroid resistance have evolved independently many times in all major groups of tetrapods. ATP1A1 has been duplicated in some groups of frogs and neofunctionlised duplicates carry the same cardiotonic steroid resistance substitutions (Q111R and N122D) found in mice, rats and other muroids.
=== Granulation === Granulation tissue is the perfused, fibrous connective tissue that replaces a fibrin clot in healing wounds. It typically grows from the base of a wound and is able to fill wounds of almost any size as it heals. HA is abundant in granulation tissue matrix. A variety of cell functions that are essential for tissue repair may attribute to this HA-rich network. These functions include facilitation of cell migration into the provisional wound matrix, cell proliferation, and organization of the granulation tissue matrix. Initiation of inflammation is crucial for the formation of granulation tissue; therefore, the pro-inflammatory role of HA as discussed above also contributes to this stage of wound healing.
Docetaxel is a cytotoxic chemotherapeutic agent. As with all chemotherapy, adverse effects are common, and many side effects have been documented. Because docetaxel is a cell-cycle-specific agent, it is cytotoxic to all dividing cells in the body. This includes tumour cells as well as hair follicles, bone marrow and other germ cells. For this reason, common chemotherapy side effects such as hair loss occur; sometimes this can be permanent. North west France are conducting a survey to establish exactly how many people are affected in this way. Independent studies show it could be as high as 6.3%, which puts it in the 'common and frequent' classification. Haematological adverse effects include neutropenia (95.5%), anaemia (90.4%), febrile neutropenia (11.0%) and thrombocytopenia (8.0%). Deaths due to toxicity accounted for 1.7% of the 2045 patients, and incidence was increased (9.8%) in patients with elevated baseline liver function tests (liver dysfunction). The use of docetaxel during chemotherapy, especially when given weekly, may lead to complications with the lacrimal drainage system. The mechanism for this problem seems to be secretion of docetaxel by the lacrimal gland which can then cause stenosis, or narrowing, of the punctum and canalicular outflow system. In most cases the primary symptoms is epiphora or tearing. When treated early most patients can avoid the need for surgery, but some cases the only cure is a conjunctivodacryocystorhinostomy in which a glass tube is placed to bypass the tear duct. Taxane-induced pneumotoxicity is rare.
Sources: en.wikipedia.org
== Funding == Gavi runs in five-year funding cycles which enables it to negotiate long-term deals with vaccine manufacturers. Industrialised countries are Gavi's principal donors, providing approximately three-quarters of the total funding. All donor governments are represented on the Gavi Board through a constituency system (i.e. one donor country will represent several donors in their constituency). In the period of 2016–2020, Gavi received US$9.3 billion, with over half of the total funding provided by the three largest donors: the UK, the Bill & Melinda Gates Foundation (BMGF), and the USA (see table). Following the Global Vaccine Summit in June 2020 hosted in the UK, US$8.8 billion was raised for the funding cycle 2021 to 2025; exceeding the target of US$7.4 billion. This included US$2 billion from the UK, US$1.6 billion from the Gates Foundation and US$1 billion from Norway. For the 2026-2030 funding cycle, the UK announced it was committing to donate £1.25 billion (roughly US$1.7 billion), The Gates Foundation announced a US$1.6 billion contribution, and the US announced it was donating US$0. As a result, Gavi announced it would fall almost US$3 billion short of its budget aim of US$11.9 billion with a total budget of US$9 billion.
Club considers the duo's collaborations—which earned them the 2013 National Board of Review (Spotlight Award)—to be career-defining moments for both of them and as vital as Scorsese's acclaimed collaborations with Robert De Niro. Author Michael K. Hammond wrote that DiCaprio built his star reputation by demonstrating his acting ability, and praised him for "revealing a character while concealing the actor" and "disappearing into [his] roles". According to Agnieszka Holland, who directed DiCaprio in Total Eclipse (1995), DiCaprio is "one of the most mature actors" she has worked with and is "courageous" in his choice of roles. Holland remarked that he does not rely on method acting but rather on a trick that allows him to truly "become the character". His Marvin's Room co-star Meryl Streep said that DiCaprio possesses the kind of unpredictability that makes his career difficult to classify, his life precarious and his work thrilling. Analyzing DiCaprio's career, film critic Philip French identified a theme of "characters who are still in the process of becoming a man" and suggested that the actor's propensity for films about dysfunctional families and characters seeking father figures alludes to his own troubled childhood. DiCaprio often plays characters who themselves are playing roles, which Caryn James says looks simple on screen but requires sophisticated acting. He tends to play antiheroes and characters who lose their mental stability as the narrative progresses.
Traceability: The ability to reconstruct the development history of a drug or medical device. Accountability: The ability to resolve who has contributed what to the development and when. Another version, ALCOA++, adds:
Oxygen primary ions are often used to investigate electropositive elements due to an increase of the generation probability of positive secondary ions, while caesium primary ions often are used when electronegative elements are being investigated. For short pulsed ion beams in static SIMS, LMIGs are most often deployed for analysis; they can be combined with either an oxygen gun or a caesium gun during elemental depth profiling, or with a C60+ or gas-cluster ion source during molecular depth profiling.
Sources: en.wikipedia.org
Freeze dryer: a more-expensive batch process for products that degrade in spray drying. Dry product is not free-flowing. Drum dryer: a less-expensive continuous process for low-value products; creates flakes instead of free-flowing powder. Pulse combustion dryer: A less-expensive continuous process that can handle higher viscosities and solids loading than a spray dryer, and sometimes yields a freeze-dry quality powder that is free-flowing.
Medical organizations recommend that patients protect themselves from UV radiation by using sunscreen. Five sunscreen ingredients have been shown to protect mice against skin tumors. However, some sunscreen chemicals produce potentially harmful substances if they are illuminated while in contact with living cells. The amount of sunscreen that penetrates into the lower layers of the skin may be large enough to cause damage. Sunscreen reduces the direct DNA damage that causes sunburn, by blocking UVB, and the usual SPF rating indicates how effectively this radiation is blocked. SPF is, therefore, also called UVB-PF, for "UVB protection factor". This rating, however, offers no data about important protection against UVA, which does not primarily cause sunburn but is still harmful, since it causes indirect DNA damage and is also considered carcinogenic. Several studies suggest that the absence of UVA filters may be the cause of the higher incidence of melanoma found in sunscreen users compared to non-users. Some sunscreen lotions contain titanium dioxide, zinc oxide, and avobenzone, which help protect against UVA rays. The photochemical properties of melanin make it an excellent photoprotectant. However, sunscreen chemicals cannot dissipate the energy of the excited state as efficiently as melanin and therefore, if sunscreen ingredients penetrate into the lower layers of the skin, the amount of reactive oxygen species may be increased. The amount of sunscreen that penetrates through the stratum corneum may or may not be large enough to cause damage.
Milk ejection reflex/Letdown reflex: in lactating (breastfeeding) mothers, oxytocin acts at the mammary glands, causing milk to be 'let down' into lactiferous ducts, from where it can be excreted via the nipple. Suckling by the infant at the nipple is relayed by spinal nerves to the hypothalamus. The stimulation causes neurons that produce oxytocin to fire action potentials in intermittent bursts; these bursts result in oxytocin pulses from the neurosecretory nerve terminals of the pituitary gland. Uterine contraction: important for cervical dilation before birth, oxytocin causes contractions during the second and third stages of labor. Oxytocin release during breastfeeding causes mild but often painful contractions during the first few weeks of lactation. This also assists the uterus in clotting the placental attachment point postpartum. However, in knockout mice lacking the oxytocin receptor, reproductive behavior and birth are normal. In male rats, oxytocin may induce erections. A burst of oxytocin is released during ejaculation in several species, including human males; its suggested function is to stimulate contractions of the reproductive tract, aiding sperm release. Human sexual response: Oxytocin levels in plasma rise during sexual stimulation and orgasm. At least two uncontrolled studies have found increases in plasma oxytocin at orgasm in both men and women. Plasma oxytocin levels are increased around the time of self-stimulated orgasm and are still higher than baseline when measured five minutes after self arousal.
=== Introduced Range === P. reptans has been introduced outside its native range into various countries across the globe. The species has been widely distributed across North America, where it can be found in the states and territories of: Bermuda, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, Ohio, Oregon, Pennsylvania, Virginia, Washington and Wisconsin. It has also been introduced in Canada in the provinces of Ontario, Québec and Nova Scotia. In Oceania the species was also introduced into the countries of Australia and New Zealand.
The four substrates of this enzyme are 4-hydroxyphenylacetic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen and a proton. Its products are homogentisic acid, oxidised NAD+, and water. The enzyme can use nicotinamide adenine dinucleotide phosphate as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxyphenylacetate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating). Other names in common use include 4-hydroxyphenylacetate 1-hydroxylase, 4-hydroxyphenylacetic 1-hydroxylase, and 4-HPA 1-hydroxylase. This enzyme participates in tyrosine metabolism.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.